Suppliers / Macfarlan Smith

Macfarlan Smith

United Kingdom Updated 9 July 2026

Macfarlan Smith is an API manufacturer based in United Kingdom. It holds 4 active US drug master files and 20 valid CEPs across a filed portfolio of 17 molecules. Its GMP standing is certified by MHRA (UK). Its most recent recorded inspection, by US FDA, closed on 29 November 2021 as VAI.

4
active US DMFs
20
valid CEPs
3
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 29 November 2021 VAI US FDA
  • 10 November 2017 VAI US FDA
  • 4 September 2015 VAI US FDA
  • 13 April 2012 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Annan, United Kingdom Not on file
Edinburgh, United Kingdom Not on file
United Kingdom, United Kingdom 3002807530

What they file, and where

Molecule Regulators Docs
Fentanyl EDQM, SFDA (Saudi Arabia) 4
Apomorphine EDQM, SFDA (Saudi Arabia), US FDA 3
Buprenorphine EDQM, US FDA 3
Morphine EDQM, SFDA (Saudi Arabia) 3
Naloxone EDQM, SFDA (Saudi Arabia), US FDA 3
Codeine EDQM 2
Methadone EDQM, SFDA (Saudi Arabia) 2
Naltrexone EDQM, US FDA 2
Oxycodone EDQM, SFDA (Saudi Arabia) 2
Alfentanil EDQM 1
Show all 17 molecules on file
Cocaine EDQM 1
Dihydrocodeine EDQM 1
Hydromorphone EDQM 1
Methylphenidate EDQM 1
Morphine Hemisulfate 2.5-Hydrate EDQM 1
Remifentanil EDQM 1
Sufentanil EDQM 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 1 None
MHRA (UK) None 2

Comparing suppliers?

Choose your molecules and target markets. Macfarlan Smith comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 29 November 2021.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates